• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amarin Corporation plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    7/29/24 5:30:08 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMRN alert in real time by email
    8-K
    false0000897448AMARIN CORP PLC\UK00-000000000008974482024-07-252024-07-25

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of Earliest Event Reported): July 25, 2024

    Amarin Corporation plc

    (Exact name of registrant as specified in its charter)

     

     

    England and Wales

    0-21392

    Not applicable

    (State or other jurisdiction

    of incorporation)

    (Commission

    File Number)

    (I.R.S. Employer

    Identification No.)

    Iconic Offices, The Greenway, Block C Ardilaun Court,

    112-114 St Stephens Green, Dublin 2, Ireland

    Not applicable

    (Address of principal executive offices)

    (Zip Code)

    Registrant’s telephone number, including area code: + 353 (0) 1 6699 020

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading
    Symbol

    Name of each exchange
    on which registered

    American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) Ordinary Share of Amarin Corporation plc

    AMRN

    NASDAQ Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

    ACTIVE/122789132.1

     


    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

    As previously disclosed, on June 3, 2024, Amarin Corporation plc (the “Company”) announced that Aaron Berg was appointed to the role of President and Chief Executive Officer (and principal executive officer) of the Company, effective June 4, 2024 (the “CEO Start Date”). In addition, Mr. Berg was also appointed as a member of the Company’s board of directors (the “Board”), effective as of the CEO Start Date.

    In connection with his appointment as President and Chief Executive Officer, Mr. Berg entered into an employment agreement with the Company, dated July 25, 2024 (the “CEO Employment Agreement”), which provides that, effective as of the CEO Start Date, Mr. Berg’s annual base salary will be $700,000 and he will have the potential to earn cash incentive compensation as determined in the sole discretion of the Board or the Remuneration Committee of the Board. In connection with his appointment, Mr. Berg will be granted a performance-based stock option to purchase 5,000,000 shares (the “Option Award”) pursuant to the Amarin Corporation plc 2020 Stock Incentive Plan, as amended (the “Plan”) and the form of Option Award agreement attached to the CEO Employment Agreement (the “Option Award Agreement”). The Option Award is earned based upon the achievement of share price hurdles ranging from $1.25 to $10.00 and the earned option shares are subject to five months of further time-based vesting once a share price hurdle has been achieved. For each share price hurdle to be achieved, the volume weighted average price of the shares over a 60 calendar-day period must equal or exceed the applicable share price hurdle. The Option Award will have an exercise price equal to the closing price of the Company’s American Depository Shares on the NASDAQ Capital Market on the date of grant, which is expected to be August 1, 2024. The Option Award is subject to acceleration and a clawback in certain circumstances in accordance with the terms of the Option Award Agreement. Pursuant to the CEO Employment Agreement, Mr. Berg has also agreed to purchase $100,000 worth of the Company’s shares using his personal funds.

    The CEO Employment Agreement provides that, if Mr. Berg’s employment is terminated by the Company without cause or if Mr. Berg resigns for good reason, in either case outside of the Change in Control Period (as defined below), Mr. Berg will be eligible to receive the following severance benefits, subject to his execution and the effectiveness of a separation agreement, including, among other things, a general release of claims in favor of the Company (the “Separation Agreement”): (i) an amount equal to 18 months of his base salary, to be paid in equal installments over the course of 18 months following the date of termination, (ii) an amount equal to 0.975 times his base salary, to be paid in a lump sum, and (iii) subject to Mr. Berg’s copayment of premium amounts at the applicable active employees’ rate and proper election to continue COBRA health coverage, payment of the portion of the premiums equal to the amount that the Company would have paid to provide health insurance to Mr. Berg had he remained employed until the earliest of (A) 18 months following termination, (B) Mr. Berg’s eligibility for group medical plan benefits under any other employer’s group medical plan or (C) the end of Mr. Berg’s COBRA health continuation period (the “COBRA Coverage”). The CEO Employment Agreement also provides that if Mr. Berg’s employment is terminated by the Company without cause or Mr. Berg resigns for good reason in either case within the 24-month period following a change in control (the “Change in Control Period”), Mr. Berg will be eligible to receive the following severance benefits, subject to his execution and the effectiveness of a Separation Agreement: (i) an amount equal to 3.3 times his base salary, to be paid in a lump sum, and (ii) the COBRA Coverage.

    The foregoing descriptions of the CEO Employment Agreement and the Option Award are only summaries and are qualified in their entirety by reference to the CEO Employment Agreement and the Option Award Agreement, which are filed as Exhibits 10.1 and 10.2, respectively, and are incorporated by reference herein.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit No.

    Description

    10.1

    CEO Employment Agreement, dated July 25, 2024, by and between Amarin Corporation plc and Aaron Berg.

    10.2

     

    Option Award Agreement (attached to Exhibit 10.1).*

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    *Certain confidential portions omitted via redaction from this Exhibit.

    * * *

     

     

     

    ACTIVE/122789132.1

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: July 29, 2024

     

    Amarin Corporation plc

     

     

     

     

    By:

    /s/ Jonathan Provoost

     

     

     

    Jonathan Provoost

    Executive Vice President, Chief Legal & Compliance Officer & Secretary

     

     

    ACTIVE/122789132.1

     


    Get the next $AMRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMRN

    DatePrice TargetRatingAnalyst
    11/20/2023Underweight
    JP Morgan
    10/25/2023$3.00 → $1.00Buy → Hold
    Jefferies
    1/6/2023$1.30 → $3.00Hold → Buy
    Jefferies
    5/6/2022Neutral → Underweight
    JP Morgan
    5/5/2022$10.00 → $3.00Outperform → Mkt Perform
    SVB Leerink
    5/5/2022$10.00 → $3.00Buy → Neutral
    H.C. Wainwright
    5/4/2022Outperform → Market Perform
    Northland Capital
    2/16/2022$11.00 → $10.00Outperform
    SVB Leerink
    More analyst ratings

    $AMRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    JP Morgan resumed coverage on Amarin

    JP Morgan resumed coverage of Amarin with a rating of Underweight

    11/20/23 7:16:51 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin downgraded by Jefferies with a new price target

    Jefferies downgraded Amarin from Buy to Hold and set a new price target of $1.00 from $3.00 previously

    10/25/23 6:25:52 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin upgraded by Jefferies with a new price target

    Jefferies upgraded Amarin from Hold to Buy and set a new price target of $3.00 from $1.30 previously

    1/6/23 7:26:32 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Fishman Peter L.

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    4/2/26 4:30:11 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Berg Aaron converted options into 4,179 units of American Depositary Shares and covered exercise/tax liability with 2,298 units of American Depositary Shares, increasing direct ownership by 2% to 82,595 units (SEC Form 4)

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    2/3/26 7:00:09 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, Chief Legal Officer Provoost Jonathan

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    2/3/26 7:00:07 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline

    DUBLIN and BRIDGEWATER, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, applauded the recommendation that the treatment of CV risk in patients with hypertriglyceridemia be part of a broader dyslipidemia management as discussed in the 2026 American College of Cardiology (ACC) / American Heart Association (AHA)/Multisociety Dyslipidemia Guideline Update.i  These newly-issued, evidenced-based recommendations summarize the clinical role of icosapent ethyl (IPE) in reducing cardiovascular (CV) risk in statin-treated patients with elevated triglycerides (TG) and full

    3/18/26 8:30:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

    DUBLIN and BRIDGEWATER, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced that additional REDUCE-IT patient subgroup analysis and additional mechanistic data on potential multifactorial biologic activities will be presented at the American College of Cardiology's Annual Scientific Session & Expo, March 28-30, 2026, in New Orleans, LA. Featured Amarin-supported abstracts to be presented by academic collaborators (italicized below) at ACC Scientific Sessions 2026 include: Oral Presentation Efficacy of Icosapent Ethyl Among Patients at Extreme Cardiovascular

    3/16/26 8:15:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology

    Peer-reviewed paper indicates icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death, providing additional insights on the effects of IPE on patient-centered measures of total disease burden DUBLIN and BRIDGEWATER, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today highlighted recently published data in the European Journal of Preventive Cardiology showing in a post hoc analysis of the landmark REDUCE-IT study that, among statin-treated participants with elevated triglycerides and known CVD or with di

    3/2/26 8:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    SEC Filings

    View All

    SEC Form PRE 14A filed by Amarin Corporation plc

    PRE 14A - AMARIN CORP PLC\UK (0000897448) (Filer)

    3/30/26 5:57:06 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Corporation plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - AMARIN CORP PLC\UK (0000897448) (Filer)

    3/27/26 5:00:07 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Amarin Corporation plc

    10-K - AMARIN CORP PLC\UK (0000897448) (Filer)

    3/2/26 5:31:01 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Berg Aaron bought $102,400 worth of Ordinary Shares (160,000 units at $0.64), increasing direct ownership by 25% to 805,380 units (SEC Form 4)

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    8/5/24 5:30:03 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Holt Patrick bought $15,724 worth of Ordinary Shares (14,426 units at $1.09), increasing direct ownership by 5% to 314,426 units (SEC Form 4)

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    1/24/24 4:31:21 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Leadership Updates

    Live Leadership Updates

    View All

    Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

    DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC Capital Partners, as a member of the Board of Directors, effective immediately. "On behalf of the board, I welcome Michael. His financial expertise, experience on other boards and, as a fellow shareholder, his shared priority to continue focusing on strategies to maximize shareholder value, make him a beneficial addition to the board at this time," said Odysseas Kostas, MD, Chairman of the Board. "I am eager to join the board and begin working with fellow directors and the s

    4/7/25 7:30:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Appoints Peter Fishman Chief Financial Officer

    DUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Peter Fishman has been appointed as Chief Financial Officer for the Company, effective immediately. He will be responsible for leading Amarin's global finance organization and will report directly to the Company's Chief Executive Officer, Aaron Berg. Most recently, Mr. Fishman served as the Company's Global Controller and principal financial and accounting officer. "Pete brings tremendous experience to his new role at Amarin, including most recently as a trusted advisor to our leadership team serving as principal financial and accounting officer for the Company," said

    12/13/24 9:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Board of Directors Announces CEO Transition

    -- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Board of Directors has appointed Aaron Berg, currently Amarin's Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as President & CEO of the Company. "On behalf of the Company's Board of Directors, I thank Pat for his contributions to Amarin, and I welcome working closely again with Aaron

    6/4/24 7:30:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Financials

    Live finance-specific insights

    View All

    Amarin Reports Fourth Quarter and Full Year 2025 Financial Results

    Strategic Initiatives and Refined Business Model Produced Financial and Operating Efficiencies Established Long-Term License and Supply Agreement to Commercialize VAZKEPA® Across Europe and Sustained U.S. Market Leadership for VASCEPA® Franchise Total of 45 Publications (Abstracts, Posters, Manuscripts) Furthering the Expansion of the VASCEPA® /VAZKEPA® (icosapent ethyl) Body of Knowledge Supported in 2025 DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the fourth quarter and full year ended December 31, 20

    2/25/26 7:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026

    DUBLIN and BRIDGEWATER, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report fourth quarter and full year 2025 financial results and conduct a conference call on Wednesday, February 25, 2026. The Company will issue a press release detailing its fourth quarter and full year 2025 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call:Via telephone: Dial in within the United States: 888-506-0062International dial in: 973-528-0011Acces

    2/11/26 8:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Reports Third Quarter 2025 Financial Results

    Company completes transition to fully partnered commercialization model across all international markets Q3 2025 performance reflects initial impact of new approach to Europe, ongoing expansion of Rest-of-World demand, continued success in managing US market, and initial operating margin improvements following corporate rightsizingTargeting sustainable positive free cash flow in 2026 DUBLIN and BRIDGEWATER, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care worldwide, today announced financial results for the third quarter of 2025. "With the reporting of Q3 2025 we usher in the next phase i

    10/29/25 7:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Amarin Corporation plc (Amendment)

    SC 13G/A - AMARIN CORP PLC\UK (0000897448) (Subject)

    12/8/23 4:26:23 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Amarin Corporation plc (Amendment)

    SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

    12/5/23 7:30:10 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Amarin Corporation plc (Amendment)

    SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

    9/5/23 4:15:30 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care